Being the most common metabolic disorder in the world Diabetes Mellitus (DM) can benefit from developing new therapeutic strategies particularly with conventional therapies struggling to properly manage it. Such therapeutic strategies can be made to achieve targeted and controlled delivery by benefiting from the advances made in the nanomedicine field. The nanomedicine field has many attractive properties that can be utilized in developing better non-conventional tools to manage and diagnose DM. DM is known to be associated with dysfunctional endothelial cells, which is a link that can be used to develop nanoformulations that can both deliver and better control the release of the anti-diabetic drug release and can restore the normal endothelial cell function. Herein we will be discussing different nanoformulations that have the ability to protect the endothelial cells, and deliver the antidiabetic drugs. Furthermore, we aim to benefit and transfer advances made in nanomedicine in different disease fields to the DM. In addition, prototypes that are proven to benefit DM and to restore the endothelial cells function can be then tested using in vivo DM models. This research is highly novel as it aims in finding better therapeutic and diagnostic tools for one of the most common diseases in the world.
- Nanomedicine status in the diabetes research area
- Nanoparticles functionalization
- Involvement of endothelial dysfunction in the development of diabetes mellitus
Dr. Nura Adam Mohamed, a graduate from the Biomedical Science Department, College of Health Sciences (CHS)-Qatar University. Who is now working as a Research Associate at the Biomedical Research Center (BRC) at Qatar University, has been awarded the L’Oréal-UNESCO for Women in Science Middle East Regional Young Talents ward 2021, which is a prestigious award designed to recognize young female scientists in the region.
Dr. Nura Mohamed, was one of nine winners in the Post-Doctorate Researchers category. She was recognized for her research towards developing nonconventional, novel therapeutic tools to prevent the development of diabetes mellitus and cardiovascular diseases. This regional initiative has recognized over 3,900 phenomenal researchers and 122 Laureates from more than 110 countries and regions since its inception 24 years ago.
Dr. Mohamed focuses on developing nano-formulations that have cardioprotective effects to battle the high prevalence of diabetes and its associated cardiovascular complications. Her research is gaining national and international attention, especially as the world moves towards targeted drug delivery, personalized medicine, and stem cell technologies, which can be achieved by using nanomaterials as drug carriers. Furthermore, she is focusing on the use of stem cell technologies in isolating progenitor cells from the patient’s blood which also aids in understanding the diseases’ progression, better establishing lab-oriented disease models in studying the different implications of the drug response on different people and help to bring these prototypes closer to the clinical trial phase.
This award will help Dr. Nura Mohamed pursue her research plan and establish collaborative ties with the leading experts in nanomedicine, cardiovascular diseases, and diabetes in Qatar, the UK, and Australia to further translate these prototypes to other disease areas. Dr. Mohamed believes that these prototypes hold great promise in the field of cardiovascular diseases and diabetes mellitus, which will provide a significant leap in developing better treatment options for diabetes mellitus and enhance the diabetes-nanomedicine field in Qatar, the GCC, and the world.